NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix (NBTX) announced a virtual event titled 'Accelerating the Future of Nanotherapeutics' scheduled for December 19, 2024, at 9:00 AM ET / 3:00 PM CET. The event will showcase the company's Curadigm Nanoprimer Platform, a new nanotherapeutic technology designed to enhance intravenously-administered therapeutics.
The presentation will feature CEO Laurent Lévy and Curadigm Head Matthieu Germain, followed by a panel discussion with experts including Margaret A. Liu, a globally recognized authority in gene therapy, vaccines, and immunotherapy. The company confirms its lead program is proceeding as planned while exploring new nanotherapeutic technologies to improve patient treatment outcomes.
Nanobiotix (NBTX) ha annunciato un evento virtuale intitolato 'Accelerare il Futuro delle Nanoterapeutiche', programmato per il 19 dicembre 2024, alle 9:00 AM ET / 3:00 PM CET. L'evento presenterà la Curadigm Nanoprimer Platform, una nuova tecnologia nanoterapeutica progettata per migliorare i trattamenti terapeutici somministrati per via endovenosa.
La presentazione includerà il CEO Laurent Lévy e il capo di Curadigm Matthieu Germain, seguita da una discussione di panel con esperti tra cui Margaret A. Liu, un'autorità di fama mondiale nella terapia genica, nei vaccini e nell'immunoterapia. L'azienda conferma che il suo programma principale sta procedendo secondo i piani, mentre esplora nuove tecnologie nanoterapeutiche per migliorare i risultati dei trattamenti per i pazienti.
Nanobiotix (NBTX) anunció un evento virtual titulado 'Acelerando el Futuro de las Nanoterapias', programado para el 19 de diciembre de 2024, a las 9:00 AM ET / 3:00 PM CET. El evento mostrará la Curadigm Nanoprimer Platform, una nueva tecnología nanoterapeutica diseñada para mejorar los tratamientos terapéuticos administrados por vía intravenosa.
La presentación contará con el CEO Laurent Lévy y el jefe de Curadigm Matthieu Germain, seguida de una discusión en panel con expertos, incluida Margaret A. Liu, una autoridad de renombre mundial en terapia génica, vacunas e inmunoterapia. La empresa confirma que su programa principal avanza según lo previsto mientras explora nuevas tecnologías nanoterapeuticas para mejorar los resultados en el tratamiento de los pacientes.
Nanobiotix (NBTX)는 '나노치료제의 미래 가속화'라는 제목의 가상 이벤트를 2024년 12월 19일 오전 9시 ET / 오후 3시 CET에 개최한다고 발표했습니다. 이 이벤트에서는 회사의 Curadigm Nanoprimer Platform이 소개되며, 이는 정맥 주사로 투여되는 치료제를 개선하기 위해 설계된 새로운 나노 치료 기술입니다.
발표에는 CEO Laurent Lévy와 Curadigm 책임자 Matthieu Germain이 참석하며, 이후 유전자 치료, 백신 및 면역 요법의 세계적 권위자인 Margaret A. Liu를 포함한 전문가 패널 토론이 이어집니다. 회사는 주요 프로그램이 계획대로 진행되고 있다고 확인하면서 환자 치료 결과를 개선하기 위해 새로운 나노 치료 기술을 탐색하고 있습니다.
Nanobiotix (NBTX) a annoncé un événement virtuel intitulé 'Accélérer le Futur des Nanothérapeutiques', prévu pour le 19 décembre 2024, à 9h00 ET / 15h00 CET. L'événement mettra en avant la Curadigm Nanoprimer Platform, une nouvelle technologie nanothérapeutique conçue pour améliorer les traitements administrés par voie intraveineuse.
La présentation sera animée par le PDG Laurent Lévy et le responsable de Curadigm Matthieu Germain, suivie d'une discussion en panel avec des experts dont Margaret A. Liu, une autorité mondialement reconnue en thérapie génique, vaccins et immunothérapie. L'entreprise confirme que son programme principal avance comme prévu tout en explorant de nouvelles technologies nanothérapeutiques pour améliorer les résultats des traitements pour les patients.
Nanobiotix (NBTX) hat eine virtuelle Veranstaltung mit dem Titel 'Die Zukunft der Nanotherapeutika beschleunigen' angekündigt, die für den 19. Dezember 2024 um 9:00 Uhr ET / 15:00 Uhr MEZ angesetzt ist. Die Veranstaltung wird die Curadigm Nanoprimer Plattform vorstellen, eine neue nanotherapeutische Technologie, die entwickelt wurde, um intravenös verabreichte Therapien zu verbessern.
Die Präsentation wird von CEO Laurent Lévy und dem Leiter von Curadigm Matthieu Germain gehalten, gefolgt von einer Podiumsdiskussion mit Experten, darunter Margaret A. Liu, eine weltweit anerkannte Autorität für Gentherapie, Impfstoffe und Immuntherapie. Das Unternehmen bestätigt, dass sein Hauptprogramm planmäßig voranschreitet, während es neue nanotherapeutische Technologien erkundet, um die Behandlungsergebnisse für Patienten zu verbessern.
- None.
- None.
- Participants can register here for the virtual event airing 9:00am ET / 3:00pm CET
PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "Accelerating the Future of Nanotherapeutics," scheduled to take place at 9:00 AM ET / 3:00 PM CET on Thursday, December 19, 2024.
Nanobiotix remains focused on advancing its lead program which is proceeding as planned. To enable further growth, Nanobiotix will leverage new nanotherapeutic technologies with the potential to improve treatment outcomes for millions of patients.
The event will feature a presentation by Laurent Lévy, PhD, Chief Executive Officer of Nanobiotix, and Matthieu Germain, PhD, Head of Curadigm at Nanobiotix. Together, they will outline the future potential of the Curadigm Nanoprimer Platform, an innovative nanotherapeutic technology designed to transform the development of intravenously-administered therapeutics.
Following the presentation, a panel discussion will bring together leading experts to explore the transformative potential of Curadigm. Participants include:
- Laurent Lévy, PhD, Chief Executive Officer, Nanobiotix
- Matthieu Germain, PhD, Head of Curadigm, Nanobiotix
- Margaret A. Liu, MD, Supervisory Board Observer, Nanobiotix, and globally recognized authority in gene therapy, vaccines, and immunotherapy
- Jeffrey Bockman, PhD, Expert Advisory and Executive Vice President, Oncology at Lumanity, who will serve as the panel moderator
Event Details:
- Title: Accelerating the Future of Nanotherapeutics
- Date: Thursday, December 19, 2024
- Time: 9:00 AM ET / 3:00 PM CET
- Format: Virtual
- Registration: Click here
Viewers can watch the event online or the replay archived on the Company’s website at www.nanobiotix.com.
About CURADIGM
Curadigm is an early-stage nanotherapeutic platform designed to disrupt the design and development IV-administered therapeutics and improve outcomes for patients. Curadigm’s Nanoprimer platform increases drug bioavailability while decreasing unintended off-target effects, specifically liver toxicity. The platform can be used with most intravenous (IV) therapeutics across multiple drug classes. Curadigm is dedicated to advancing therapeutic development based on our deep understanding of how drugs interact with the body, to impact both known and novel drugs across multiple clinical indications.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2023 universal registration document filed with the AMF on April 24, 2024, in Nanobiotix’ 2024 semi-annual report under the caption “Supplemental Risk Factor” filed with the SEC on Form 6-K and with AMF on September 18 2024, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
| FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
Attachments
FAQ
When is Nanobiotix (NBTX) hosting its nanotherapeutics virtual event?
What is the Curadigm Nanoprimer Platform that NBTX will discuss?
Who are the key speakers at the NBTX December 19 virtual event?
How can investors attend the NBTX nanotherapeutics virtual event?
